Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CET

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
12/10 ASTRAZENECA : AZ and Lilly come together to battle Alzheimers
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09 ASTRAZENECA : US FDA accepts first biologics license application for AstraZeneca..
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09 TOP NEWS : AstraZeneca Receives FDA Priority Status For Durvalumab
12/09 ASTRAZENECA : FDA accepts durvalumab for BLA in bladder cancer
12/09 ASTRAZENECA PLC (NYSE : AZN) Cuts Jobs, Signs New Collaboration With Eli Lilly a..
12/08 ASTRAZENECA : cuts 700 U.S. jobs, including at its headquarters in Wilmington
12/08 ASTRAZENECA : cuts about 700 jobs, including 120 in Delaware
12/08 ASTRAZENECA : Tagrisso shows promise in treating form of advanced lung cancer
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/09 Analyst coverage update
12/09 CANCER IMMUNOTHERAPY MARKET : 2016 Takeaways And What To Expect In 2017
12/09 FDA accepts AstraZeneca's marketing application for durvalumab for bladder ca..
12/09 Trading in AstraZeneca halted pending news
12/09 Lilly not giving up on Alzheimer's, teams up with AstraZeneca to develop earl..
Advertisement
Financials ($)
Sales 2016 22 946 M
EBIT 2016 6 505 M
Net income 2016 2 406 M
Debt 2016 11 470 M
Yield 2016 5,16%
P/E ratio 2016 26,57
P/E ratio 2017 24,93
EV / Sales 2016 3,47x
EV / Sales 2017 3,69x
Capitalization 68 135 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 64,7 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-7.29%68 135
JOHNSON & JOHNSON9.29%305 407
ROCHE HOLDING LTD.-17.58%193 824
PFIZER INC.-4.15%192 367
NOVARTIS AG-18.49%182 959
MERCK & CO., INC.15.92%168 820
More Results